Search Results for "Triphasil"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Triphasil. Results 1 to 6 of 6 total matches.
See also: levonorgestrel

An Emergency Contraception Kit

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998  (Issue 1038)
Triphasil (Wyeth-Ayerst) 4 30 µg 0.125 levonorgestrel 4 27.47 Trivora (Watson) 4 30 µg 0.125 ...
High doses of estrogens, with or without a progestin, have been used for many years to prevent pregnancy after unprotected coitus (Medical Letter, 31:93, 1989). Now the FDA has approved marketing of the Preven Emergency Contraceptive Kit (Gynetics, Inc.) for this indication. The kit, which will require a prescription, includes four tablets, each containing 50 g of ethinyl estradiol and 0.25 mg of levonorgestrel, and a pregnancy test to rule out a pre-existing pregnancy, which would be a contraindication to taking the hormones.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):102-3 |  Show IntroductionHide Introduction

Ortho Evra - A Contraceptive Patch

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002  (Issue 1122)
and menstrual cramps. In a comparison with the oral contraceptive Triphasil, breast discomfort (18.7% vs. 5.8 ...
A transdermal contraceptive patch (Ortho Evra — Ortho-McNeil) has been approved by the FDA. Each 20 cm2 patch contains 6 mg of the progestin norelgestromin (the active metabolite of norgestimate) and 0.75 mg of ethinyl estradiol.
Med Lett Drugs Ther. 2002 Jan 21;44(1122):8 |  Show IntroductionHide Introduction

Desogestrel - A New Progestin for Oral Contraception

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993  (Issue 902)
, 0.075, 0.125)Triphasil-21 (Wyeth-Ayerst) 4 30, 40, 30 680 1.925 20.50 Ovcon 35 21, 28 (Mead Johnson ...
Desogen (Organon) and Ortho-Cept (Ortho), two oral contraceptives each containing a low dose (30 mcg) of the estrogen ethinyl estradiol plus 150 mcg of the progestin desogestrel, were recently approved by the US Food and Drug Administration for marketing in the USA. They are the first US oral contraceptives to contain desogestrel, which is widely used in oral contraceptive combination products in other countries. Desogestrel is one of three new progestins (norgestimate and gestodene are the others) considered less androgenic than previously available progestins (L Speroff et al, Obstet...
Med Lett Drugs Ther. 1993 Aug 6;35(902):73-4 |  Show IntroductionHide Introduction

Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2000  (Issue 1078)
) ethinyl estradiol (30, 40, 30) levonorgestrel (0.05, 0.075, 0.125) 28.02 Triphasil 21 (Wyeth-Ayerst) 4 ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Med Lett Drugs Ther. 2000 May 15;42(1078):42-4 |  Show IntroductionHide Introduction

Yasmin -- an Oral Contraceptive With a New Progestin

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002  (Issue 1133)
estradiol (30, 40, 30) 28.98 Triphasil 21 (Wyeth-Ayerst) 4 levonorgestrel (0.05, 0.075, 0.125) ethinyl ...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
Med Lett Drugs Ther. 2002 Jun 24;44(1133):55-7 |  Show IntroductionHide Introduction

Nefazodone for Depression

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995  (Issue 946)
trazodone triazolam Tri-Levlen Triphasil venlafaxine Wellbutrin Xanax Zoloft Serzone sertraline Nefazodone ...
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
Med Lett Drugs Ther. 1995 Apr 14;37(946):33-5 |  Show IntroductionHide Introduction